News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
543,211 Results
Type
Article (42520)
Company Profile (78)
Press Release (500613)
Section
Business (163674)
Career Advice (2105)
Deals (29099)
Drug Delivery (98)
Drug Development (70334)
Employer Resources (139)
FDA (13267)
Job Trends (12102)
News (283586)
Policy (30295)
Tag
Academia (2312)
Alliances (49474)
Alzheimer's disease (1146)
Approvals (13204)
Artificial intelligence (128)
Bankruptcy (273)
Best Places to Work (9748)
Breast cancer (112)
Cancer (976)
Cardiovascular disease (85)
Career advice (1773)
Cell therapy (221)
Clinical research (55444)
Collaboration (386)
Compensation (172)
COVID-19 (2565)
Data (998)
Diabetes (150)
Diagnostics (4898)
Drug pricing (84)
Earnings (65076)
Employer resources (125)
Events (74188)
Executive appointments (226)
FDA (13738)
Funding (302)
Gene therapy (173)
GLP-1 (618)
Government (4449)
Healthcare (15286)
Infectious disease (2651)
Inflammatory bowel disease (93)
Interviews (374)
IPO (12824)
Job creations (2709)
Job search strategy (1501)
Layoffs (338)
Legal (8080)
Lung cancer (153)
Manufacturing (159)
Medical device (9318)
Medtech (9322)
Mergers & acquisitions (16369)
Metabolic disorders (416)
Neuroscience (1393)
NextGen Class of 2024 (5220)
Non-profit (3901)
Northern California (1184)
Obesity (245)
Opinion (201)
Patents (96)
People (39199)
Phase I (16805)
Phase II (24047)
Phase III (19168)
Pipeline (444)
Policy (78)
Postmarket research (2453)
Preclinical (7283)
Radiopharmaceuticals (222)
Rare diseases (194)
Real estate (4036)
Regulatory (19048)
Research institute (2018)
Resumes & cover letters (320)
Southern California (1019)
Startups (2603)
United States (10582)
Vaccines (608)
Weight loss (198)
Date
Today (63)
Last 7 days (534)
Last 30 days (3094)
Last 365 days (29541)
2024 (27079)
2023 (32822)
2022 (42430)
2021 (45741)
2020 (44239)
2019 (38018)
2018 (28630)
2017 (27042)
2016 (26126)
2015 (29845)
2014 (24397)
2013 (20864)
2012 (21493)
2011 (21599)
2010 (20148)
Location
Africa (797)
Arizona (105)
Asia (32941)
Australia (5740)
California (2576)
Canada (1035)
China (219)
Colorado (123)
Connecticut (127)
Europe (78428)
Florida (386)
Georgia (96)
Illinois (262)
Indiana (160)
Kansas (73)
Maryland (512)
Massachusetts (2000)
Michigan (117)
Minnesota (160)
New Jersey (830)
New York (796)
North Carolina (566)
Northern California (1184)
Ohio (112)
Pennsylvania (660)
South America (1087)
Southern California (1019)
Texas (351)
Utah (76)
Washington State (268)
543,211 Results for "eckert and ziegler ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
November 13, 2024
·
8 min read
Drug Development
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, announced that it has received encouraging feedback from the U.S. FDA following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registration study with its radiopharmaceutical diagnostic Ga68-PentixaFor in Primary Aldosteronism.
June 25, 2024
·
3 min read
BioMidwest
Eckert & Ziegler to Supply Nucleus RadioPharma with Therapeutic Radioisotopes Ac-225 and Lu-177
Eckert & Ziegler and Nucleus RadioPharma signed extensive supply agreements for major therapeutic radioisotopes.
January 31, 2024
·
3 min read
BioMidwest
Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
Eckert & Ziegler and PharmaLogic Holdings Corp. have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225.
October 10, 2023
·
2 min read
BioMidwest
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
Eckert & Ziegler and a subsidiary of POINT Biopharma Global Inc. have signed an agreement on the supply of Actinium-225.
April 4, 2023
·
3 min read
RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals
RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, has expanded its radiopharmaceutical contract development and manufacturing
April 4, 2024
·
3 min read
BioMidwest
Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
NorthStar Medical Radioisotopes, LLC and Eckert & Ziegler Isotope Technologies Dresden announced an agreement for the purchase of hot cells and related equipment for NorthStar’s dedicated non-carrier-added actinium-225 production facility.
October 11, 2022
·
4 min read
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
Telix Pharmaceuticals Limited announces a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG for highly pure no-carrier-added lutetium-177, a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation investigational products.
February 8, 2022
·
4 min read
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
1 of 54,322
Next